← All stocks

Enliven Therapeutics, Inc.

ELVN Net selling
CIK 0001672619 #1481 in the set updated 22 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$76.81M
$8.93M on a plan · $15.90M straight out of an exercise
Sold at will
$51.98M
7 of 81 sales
Net
−$76.81M
−$51.98M against sales at will

By person

10 insiders · 83 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
ORBIMED ADVISORS LLC entity
10% owner
$51.68M (6)
−$51.68M
6,555,102
8.95%
$337.47M
−14.8%
Derynck Mika K
Director
$9.56M (1) scheduled
−$9.56M
0
0.0000%
$0.00
Collins Helen Louise
CHIEF MEDICAL OFFICER
$5.39M (24) scheduled
−$5.39M
25,000
0.0341%
$1.29M
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
$4.91M (13) scheduled
−$4.91M
758,938
1.04%
$39.07M
−29.6%
Patel Anish
CHIEF OPERATING OFFICER
$1.74M (7) scheduled
−$1.74M
235,011
0.3207%
$12.10M
−31.7%
Hohl Benjamin
CHIEF FINANCIAL OFFICER
$1.60M (15) scheduled
−$1.60M
38,000
0.0519%
$1.96M
Kunkel Lori Anne
Director
$850.25K (5) scheduled
−$850.25K
41,884
0.0572%
$2.16M
−8.8%
Kintz Samuel
PRESIDENT AND CEO
$669.70K (4) scheduled
−$669.70K
890,392
1.22%
$45.84M
−15.0%
Heyman Richard A.
Director
$413.38K (6) scheduled
−$413.38K
146,320
0.1997%
$7.53M
−13.4%
Ballal Rahul D.
Director
22,341
0.0305%
$1.15M
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
Hohl Benjamin
17 Aug 2026
CHIEF FINANCIAL OFFICER
Sold on a plan
1,388
$59.35
$82.38K
Hohl Benjamin
17 Aug 2026
CHIEF FINANCIAL OFFICER
Sold on a plan
4,630
$58.35
$270.17K
Kunkel Lori Anne
6 Jul 2026
Director
Sold on a plan
5,889
$50.84
$299.42K
Kunkel Lori Anne
6 Jul 2026
Director
Sold on a plan
4,111
$49.98
$205.48K
Kunkel Lori Anne
5 Jun 2026
Director
Sold on a plan
354
$35.82
$12.68K
Kunkel Lori Anne
5 Jun 2026
Director
Sold on a plan
1,867
$35.36
$66.01K
Kunkel Lori Anne
5 Jun 2026
Director
Sold on a plan
7,779
$34.28
$266.66K
Heyman Richard A.
17 Feb 2026
Director
Sold on a plan indirect
1,230
$26.18
$32.20K
Lyssikatos Joseph P
6 Feb 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
5,000
$29.04
$145.22K
Heyman Richard A.
20 Jan 2026
Director
Sold on a plan indirect
718
$26.96
$19.35K
Heyman Richard A.
20 Jan 2026
Director
Sold on a plan indirect
512
$26.46
$13.55K
Lyssikatos Joseph P
20 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
14,509
$26.90
$390.28K
Lyssikatos Joseph P
20 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
5,491
$26.37
$144.81K
Heyman Richard A.
9 Jan 2026
Director
Sold on a plan indirect
4,285
$25.00
$107.13K
Lyssikatos Joseph P
9 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
50,000
$29.13
$1.46M
Lyssikatos Joseph P
9 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
41,198
$24.90
$1.03M
Patel Anish
9 Jan 2026
CHIEF OPERATING OFFICER
Sold on a plan indirect
243
$28.50
$6.93K
Patel Anish
9 Jan 2026
CHIEF OPERATING OFFICER
Sold on a plan indirect
48,057
$27.98
$1.34M
Heyman Richard A.
8 Jan 2026
Director
Sold on a plan indirect
8,015
$25.04
$200.66K
Heyman Richard A.
8 Jan 2026
Director
Sold on a plan indirect
1,620
$25.00
$40.50K
Lyssikatos Joseph P
8 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
33,802
$24.92
$842.47K
Lyssikatos Joseph P
8 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
7,500
$20.13
$150.96K
Lyssikatos Joseph P
19 Dec 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
5,000
$16.84
$84.21K
Patel Anish
8 Dec 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
1,705
$21.78
$37.13K
Patel Anish
8 Dec 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
4,958
$20.76
$102.94K
Lyssikatos Joseph P
19 Nov 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
492
$23.09
$11.36K
Lyssikatos Joseph P
19 Nov 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
12,008
$22.30
$267.79K
Kintz Samuel
17 Nov 2025
PRESIDENT AND CEO
Sold on a plan indirect
12,500
$21.82
$272.74K
Patel Anish
7 Nov 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
613
$17.94
$11.00K
Patel Anish
7 Nov 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
6,054
$17.35
$105.04K
Lyssikatos Joseph P
20 Oct 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
12,500
$22.08
$276.03K
Kintz Samuel
17 Oct 2025
PRESIDENT AND CEO
Sold on a plan indirect
12,500
$21.33
$266.65K
Patel Anish
7 Oct 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
6,667
$20.10
$133.99K
Kintz Samuel
26 Sep 2025
PRESIDENT AND CEO
Sold on a plan indirect
3,700
$20.06
$74.23K
Lyssikatos Joseph P
26 Sep 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
4,000
$20.25
$81.01K
Kintz Samuel
23 Sep 2025
PRESIDENT AND CEO
Sold on a plan indirect
2,800
$20.03
$56.08K
Lyssikatos Joseph P
23 Sep 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
1,500
$20.03
$30.05K

What was left out

Form 4 filings counted 56
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 37
Sales straight out of an exercise 37
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 450,825
History held since 16 Mar 2020